CA2255867A1 - Chitosan induced immunopotentiation - Google Patents

Chitosan induced immunopotentiation

Info

Publication number
CA2255867A1
CA2255867A1 CA002255867A CA2255867A CA2255867A1 CA 2255867 A1 CA2255867 A1 CA 2255867A1 CA 002255867 A CA002255867 A CA 002255867A CA 2255867 A CA2255867 A CA 2255867A CA 2255867 A1 CA2255867 A1 CA 2255867A1
Authority
CA
Canada
Prior art keywords
chitosan
immunopotentiation
chitosan induced
induced immunopotentiation
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002255867A
Other languages
French (fr)
Other versions
CA2255867C (en
Inventor
Joseph S. Podolski
Mitzi L. Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repros Therapeutics Inc
Original Assignee
Zonagen, Inc.
Joseph S. Podolski
Mitzi L. Martinez
Repros Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zonagen, Inc., Joseph S. Podolski, Mitzi L. Martinez, Repros Therapeutics, Inc. filed Critical Zonagen, Inc.
Priority to PCT/US1997/005094 priority Critical patent/WO1998042374A1/en
Priority to AU23478/97A priority patent/AU2347897A/en
Priority to CA002255867A priority patent/CA2255867C/en
Priority to EP97916251A priority patent/EP0914154A1/en
Publication of CA2255867A1 publication Critical patent/CA2255867A1/en
Application granted granted Critical
Publication of CA2255867C publication Critical patent/CA2255867C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Methods and compositions for potentiating an immune response are disclosed which incorporate chitosan as an immunopotentiating adjuvant. Administration of the compositions of the invention is effected by various routes.
CA002255867A 1997-03-25 1997-03-25 Chitosan induced immunopotentiation Expired - Fee Related CA2255867C (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/US1997/005094 WO1998042374A1 (en) 1997-03-25 1997-03-25 Chitosan induced immunopotentiation
AU23478/97A AU2347897A (en) 1997-03-25 1997-03-25 Chitosan induced immunopotentiation
CA002255867A CA2255867C (en) 1997-03-25 1997-03-25 Chitosan induced immunopotentiation
EP97916251A EP0914154A1 (en) 1997-03-25 1997-03-25 Chitosan induced immunopotentiation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1997/005094 WO1998042374A1 (en) 1997-03-25 1997-03-25 Chitosan induced immunopotentiation
CA002255867A CA2255867C (en) 1997-03-25 1997-03-25 Chitosan induced immunopotentiation

Publications (2)

Publication Number Publication Date
CA2255867A1 true CA2255867A1 (en) 1998-10-01
CA2255867C CA2255867C (en) 2008-02-05

Family

ID=25680666

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002255867A Expired - Fee Related CA2255867C (en) 1997-03-25 1997-03-25 Chitosan induced immunopotentiation

Country Status (4)

Country Link
EP (1) EP0914154A1 (en)
AU (1) AU2347897A (en)
CA (1) CA2255867C (en)
WO (1) WO1998042374A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035994A2 (en) * 1999-11-04 2001-05-25 Zonagen, Inc. Chitosan induced immunopotentiation
US7588774B2 (en) 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
EP2068917A2 (en) * 2006-09-22 2009-06-17 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Compositions and methods for chitosan enhanced immune response
KR101342641B1 (en) * 2009-06-25 2013-12-20 주식회사 바이오리더스 Composition for Adjuvant Comprising Poly-Gamma-Glutamic Acid-Chitosan Nanoparticle

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
WO1996009805A2 (en) * 1994-09-23 1996-04-04 Zonagen, Inc. Chitosan induced immunopotentiation
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions

Also Published As

Publication number Publication date
AU2347897A (en) 1998-10-20
WO1998042374A1 (en) 1998-10-01
EP0914154A1 (en) 1999-05-12
CA2255867C (en) 2008-02-05

Similar Documents

Publication Publication Date Title
WO1996009805A3 (en) Chitosan induced immunopotentiation
CA2237529A1 (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
AU6535698A (en) Protection of living systems from the adverse effects of stress
CA2216535A1 (en) Protein kinase c inhibitors
CA2304568A1 (en) Olanzapine pamoate formulations
WO2002013857A3 (en) A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
CA2129288A1 (en) Phosphonooxymethyl Esters of Taxane Derivatives
FR2762843B1 (en) NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2182582A1 (en) Compositions containing micronized nebivolol
HUP9903823A3 (en) Use of sibutramine analogues for the preparation of pharmaceutical compositions suitable for lowering lipid levels
CA2177668A1 (en) Mammalian vaccine compositions comprising squalene or squalane, glycerol and a surfactant as an adjuvant
EP2275126A3 (en) Protein-based streptococcus pneumoniae vaccines
CA2177667A1 (en) Mammalian vaccine compositions comprising squalene or squalane, lecithin and a polyoxyethylene sorbitan ester as an adjuvant
AP9400621A0 (en) Influenza vaccine compositions
CA2255867A1 (en) Chitosan induced immunopotentiation
IL116828A0 (en) Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions
WO2002017961A1 (en) Vaccine preparation containing fatty acid as component
WO2001035994A3 (en) Chitosan induced immunopotentiation
AU6849198A (en) Neurotrypsin
CA2154871A1 (en) Farnesyl:protein transferase inhibitors as anticancer agents
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
AU2775692A (en) Recombinant influenza virus vaccine compositions
IL116747A0 (en) Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions
FR2708855B1 (en) Immunoadjuvant or immunostimulatory pharmaceutical compositions.
AU5994796A (en) Modified kojibiosides analogues

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130325